Cargando…
Integrated molecular and clinical analysis of BRAF-mutant glioma in adults
BRAF mutations are a significant driver of disease in pediatric low-grade glioma, but the implications of BRAF alterations on the clinical course and treatment response in adult glioma remain unclear. Here, we characterize a multi-institutional cohort of more than 300 patients (>200 adults) with...
Autores principales: | Schreck, Karisa C., Langat, Pinky, Bhave, Varun M., Li, Taibo, Woodward, Eleanor, Pratilas, Christine A., Eberhart, Charles G., Bi, Wenya Linda |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9975216/ https://www.ncbi.nlm.nih.gov/pubmed/36854806 http://dx.doi.org/10.1038/s41698-023-00359-y |
Ejemplares similares
-
ECOA-10. Integrated genomic and clinical analysis of BRAF-mutated glioma in adults
por: Langat, Pinky, et al.
Publicado: (2021) -
BRAF Mutations and the Utility of RAF and MEK Inhibitors in Primary Brain Tumors
por: Schreck, Karisa C., et al.
Publicado: (2019) -
BRAF V600E-Mutant Glioblastoma with Extracranial Metastases Responsive to Combined BRAF and MEK Targeted Inhibition: A Case Report
por: Munjapara, Vasu, et al.
Publicado: (2022) -
Deconvoluting Mechanisms of Acquired Resistance to RAF Inhibitors in BRAF(V600E)-Mutant Human Glioma
por: Schreck, Karisa C., et al.
Publicado: (2021) -
Combination MEK and mTOR inhibitor therapy is active in models of glioblastoma
por: Schreck, Karisa C, et al.
Publicado: (2020)